Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study

BACKGROUND AND OBJECTIVE: Once-daily oral fingolimod is approved in the EU as escalation treatment for adult patients with highly active relapsing multiple sclerosis (MS). The efficacy and safety profiles of fingolimod have been well established in a large clinical development programme and several...

Descripción completa

Detalles Bibliográficos
Autores principales: Tichá, Veronika, Kodým, Roman, Počíková, Zuzana, Kadlecová, Pavla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250638/
https://www.ncbi.nlm.nih.gov/pubmed/27785735
http://dx.doi.org/10.1007/s40261-016-0471-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250638/
https://www.ncbi.nlm.nih.gov/pubmed/27785735
http://dx.doi.org/10.1007/s40261-016-0471-2

Ejemplares similares